Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Express Scripts
Fish and Richardson
Accenture
AstraZeneca
Cipla
Chubb
Boehringer Ingelheim
Chinese Patent Office

Generated: April 25, 2018

DrugPatentWatch Database Preview

PERTOFRANE Drug Profile

« Back to Dashboard

Which patents cover Pertofrane, and what generic alternatives are available?

Pertofrane is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PERTOFRANE is desipramine hydrochloride. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.
Drug patent expirations by year for PERTOFRANE
Medical Subject Heading (MeSH) Categories for PERTOFRANE
Synonyms for PERTOFRANE
[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamine hydrochloride
10-11-Dihydro-N-methyl-5H-dibenz(Z)[b,f]azepine-5-propanamine hydrochloride
10,11-Dihydro-5-(3-(methylamino)prop-yl)-5h-dibenz(b,f)azepine hydro-chloride
10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine hydrochloride
10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine monohydrochloride
10,11-Dihydro-N-methyl-5H-dibenz-[b,f]azepine hydrochloride
10,f]azepine hydrochloride
10,f]azepine monohydrochloride
1Y58DO4MY1
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine hydrochloride
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine hydrochloride
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;hydrochloride
5-(3-Methylaminopropyl)-5H-dibenz[b,f]azepine hydrochloride
50-47-5 (Parent)
58-28-6
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, hydrochloride
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, monohydrochloride
5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, hydrochloride
5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, monohydrochloride
5H-Dibenz[b, 10,11-dihydro-N-methyl-, monohydrochloride
AC1L2324
AKOS015994722
AN-083
B7261
BG0162
CAS-58-28-6
CC-26348
CCG-38909
CHEBI:4449
CHEMBL1696
CPD000036827
CS-8201
CTK8F9062
D 3900
D00812
Demethylimipramine hydrochloride
Desimipramine hydrochloride
Desimipramine, hydrochloride
Desipramine Hcl
Desipramine hydrochloride
Desipramine hydrochloride (JAN/USP)
Desipramine hydrochloride [USAN:JAN]
Desipramine hydrochloride [USAN:USP:JAN]
Desipramine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Desipramine hydrochloride solution, drug standard, 1.0 mg/mL in methanol
Desipramine hydrochloride, >=98% (TLC), powder
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Desipramine Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Desipramine monohydrochloride
Desiprimine
Desmethylimipramine chloride
Desmethylimipramine hydrochloride
Desmethylimipramine monohydrochloride
Desmethylimipramine-hydrochloride
DMI hydrochloride
DSSTox_CID_26942
DSSTox_GSID_46942
DSSTox_RID_82024
DTXSID9046942
EINECS 200-373-1
Epitope ID:224551
EU-0100358
EX 4355
EX-4355
FT-0603109
G 35020
G-35020
GMI
HMS1569E07
HMS1920C22
HY-B1272
Imipraminedemethyl hydrochloride
iren
JB 8181
JB-8181
KS-1296
LP00358
LS-60422
LT00771924
MFCD00058108
MLS000028418
MLS000038088
MLS001056757
MLS002222246
MLS002548871
MolPort-000-917-727
N-(.gamma.-Methylaminopropyl)iminodibenzyl hydrochloride
N-(gamma-Methylaminopropyl)iminodibenzyl hydrochloride
NC00681
NCGC00015340-02
NCGC00015340-14
NCGC00093794-01
NCGC00093794-02
NCGC00093794-03
NCGC00093794-04
NCGC00093794-05
NCGC00261043-01
Norpolake
Norpramin
Norpramin (TN)
Nortimil
NSC 114901
NSC-114901
NSC-756719
NSC114901
NSC756719
Opera_ID_943
Pertofran
Pertofrin
Pertrofan
Petylyl
Pharmakon1600-01500227
Prestwick_706
REGID_for_CID_65327
RMI 9,384A
RMI-9384A
SAM002264605
SC-57976
SCHEMBL41992
SMR000036827
SPECTRUM1500227
SR-01000003060
SR-01000003060-2
Tox21_110129
Tox21_110129_1
Tox21_500358
UNII-1Y58DO4MY1
VA10690
WLN: T C676 BN&T&J B3M1 &GH
XAEWZDYWZHIUCT-UHFFFAOYSA-N

US Patents and Regulatory Information for PERTOFRANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PERTOFRANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
US Department of Justice
Argus Health
Boehringer Ingelheim
Dow
Queensland Health
Daiichi Sankyo
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.